Compare WES & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WES | UTHR |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 20.3B |
| IPO Year | 2008 | 1999 |
| Metric | WES | UTHR |
|---|---|---|
| Price | $40.05 | $488.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $41.20 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 1.6M | 424.3K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 3.38 | ★ 26.38 |
| Revenue | ★ $3,740,425,000.00 | $3,128,400,000.00 |
| Revenue This Year | $8.40 | $13.64 |
| Revenue Next Year | $6.96 | $5.78 |
| P/E Ratio | ★ $11.83 | $18.55 |
| Revenue Growth | 5.81 | ★ 13.50 |
| 52 Week Low | $33.60 | $266.98 |
| 52 Week High | $43.33 | $492.62 |
| Indicator | WES | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 68.10 |
| Support Level | $38.79 | $470.13 |
| Resistance Level | $39.73 | $492.62 |
| Average True Range (ATR) | 0.62 | 10.72 |
| MACD | 0.09 | -0.53 |
| Stochastic Oscillator | 67.52 | 89.55 |
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.